AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24780728 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g dried plum/d
Number of subjects: 160
Study 24780728 — intervention group
Group type: COMPARATOR
Intervention: 75 g dried apple/d (comparative control)
Number of subjects: 160
Study 23248893 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-directional power toothbrush (Oral-B Vitality TriZone)
Number of subjects: 36
Study 23248893 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (ADA reference soft manual brush)
Number of subjects: 36
Study 20447049 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection combined with 10 sessions of physical and occupational therapy followed by 10 sessions of neuromuscular electrical stimulation on the wrist extensors
Number of subjects: 10
Study 19192750 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 19
Study 19192750 — intervention group
Group type: COMPARATOR
Intervention: No-MUF
Number of subjects: 19
Study 15733028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 4995
Study 15733028 — intervention group
Group type: COMPARATOR
Intervention: Combined sequential HRT
Number of subjects: 4995
Study 15562740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain tracker instrument
Number of subjects: 102
Study 15562740 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 11078267 — intervention group
Group type: EXPERIMENTAL
Intervention: Young diabetic patients (yDM)
Number of subjects: 20
Study 11078267 — intervention group
Group type: COMPARATOR
Intervention: Older non-diabetic patients (o non-DM)
Number of subjects: 20
Study 11078267 — intervention group
Group type: COMPARATOR
Intervention: Young non-diabetic patients (y non-DM)
Number of subjects: 20
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumocystis carinii in AIDS patients
Number of subjects: 36
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) in AIDS patients
Number of subjects: 36
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumocystis carinii in symptomatic HIV infants
Number of subjects: 36
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) in liver tissue from AIDS infants
Number of subjects: 36
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infections ante-mortem in AIDS patients
Number of subjects: 36
Study 8985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis in post-mortem lung tissue
Number of subjects: 36
Study 1335203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphonoformate 3% drops
Number of subjects: 20
Study 1335203 — intervention group
Group type: COMPARATOR
Intervention: Trifluorthymidine 1% drops
Number of subjects: 20
Study 6363155 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine thiazolidinecarboxylate (800 mg/day for 40 days)
Number of subjects: 44
Study 6363155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31489424 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral health education
Number of subjects: 150
Study 31489424 — intervention group
Group type: COMPARATOR
Intervention: Routine oral hygiene education (Control)
Number of subjects: 150
Study 29858746 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS)
Number of subjects: 171
Study 29858746 — intervention group
Group type: COMPARATOR
Intervention: Traditional spinal cord stimulation (SCS)
Number of subjects: 171
Study 27481881 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10mg)
Number of subjects: 0
Study 27481881 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (2×300ml)
Number of subjects: 0
Study 23488690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 23488690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Losartan
Number of subjects: 0
Study 23488690 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 0
Study 23145844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 1433
Study 23145844 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1433
Study 20519079 — intervention group
Group type: EXPERIMENTAL
Intervention: Yitongshu injection (4 ml) into the Zusanli point on both sides 11 hours or 23 hours after administration of the drugs.
Number of subjects: 28
Study 20519079 — intervention group
Group type: COMPARATOR
Intervention: Midazolam combined with fentanyl (control group).
Number of subjects: 28
Study 17425758 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-enalapril combination
Number of subjects: 99
Study 17425758 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 99
Study 17425758 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 99
Study 15781019 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (1.2 g/day for 6 weeks)
Number of subjects: 20
Study 15781019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12217281 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter directed thrombolysis followed by anticoagulation
Number of subjects: 35
Study 12217281 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 35
Study 10809859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum ointment
Number of subjects: 0
Study 10809859 — intervention group
Group type: COMPARATOR
Intervention: Solar-simulated radiation (SSR)
Number of subjects: 0
Study 10809859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperforin (in vivo and in vitro)
Number of subjects: 0
Study 10809859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperforin (in vitro)
Number of subjects: 0
Study 10809859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperforin
Number of subjects: 0
Study 9257602 — intervention group
Group type: EXPERIMENTAL
Intervention: Changed programme
Number of subjects: 0
Study 9257602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1739365 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 40
Study 1739365 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 6433319 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1 U/mL) added to intravenous alimentation solutions
Number of subjects: 26
Study 6433319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 26
Study 31053295 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antibodies to neuronal proteins
Number of subjects: 50
Study 31053295 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (Control)
Number of subjects: 50
Study 31053295 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive status in patients with ME
Number of subjects: 50
Study 30622487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 50
Study 30622487 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 50
Study 28685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP) in addition to conventional therapy
Number of subjects: 120
Study 28685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 120
Study 28685542 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study 26158927 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM‐IOL (heparin surface modified intraocular lens)
Number of subjects: 102
Study 26158927 — intervention group
Group type: COMPARATOR
Intervention: UC‐IOL (uncoated intraocular lens)
Number of subjects: 102
Study 26158927 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM‐IOL
Number of subjects: 102
Study 26158927 — intervention group
Group type: COMPARATOR
Intervention: UC‐IOL
Number of subjects: 102
Study 23384411 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of human umbilical tissue-derived cells (hUTC) into the nucleus pulposus (NP)
Number of subjects: 30
Study 23384411 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of hydrogel carrier alone
Number of subjects: 30
Study 23384411 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of human umbilical tissue-derived cells (hUTC) with hydrogel carrier
Number of subjects: 30
Study 23384411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 23384411 — intervention group
Group type: COMPARATOR
Intervention: Punctured group (no treatment)
Number of subjects: 30
Study 21740403 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy as an adjunct to pharmacological therapy
Number of subjects: 60
Study 21740403 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacological therapy only)
Number of subjects: 60
Study 21740403 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60
Study 18505387 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB, 1 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 2)
Number of subjects: 64
Study 18505387 — intervention group
Group type: COMPARATOR
Intervention: AmB, 0.7 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 1)
Number of subjects: 64
Study 18505387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 64
Study 17063641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyme-ivy combination syrup (5.4 ml three times daily for 11 days)
Number of subjects: 361
Study 17063641 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 361
Study 17063641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyme-ivy combination syrup
Number of subjects: 361
Study 17063641 — intervention group
Group type: COMPARATOR
Intervention: Thyme-ivy combination syrup and Placebo syrup
Number of subjects: 361
Study 12953167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine-131 (131I) treatment (141 +/- 85 MBq)
Number of subjects: 40
Study 12953167 — intervention group
Group type: COMPARATOR
Intervention: Control group (spontaneous remission)
Number of subjects: 40
Study 12953167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume at baseline and at 3 months
Number of subjects: 40
Study 12953167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume at 6 months
Number of subjects: 40
Study 12953167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume at 3 months
Number of subjects: 40
Study 10782840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rhGH (12 IU/m2/week)
Number of subjects: 20
Study 10782840 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rhGH (24 IU/m2/week)
Number of subjects: 20
Study 10782840 — intervention group
Group type: COMPARATOR
Intervention: Control (age matched children)
Number of subjects: 20
Study 9324342 — intervention group
Group type: COMPARATOR
Intervention: CVPP chemotherapy (3 cycles)
Number of subjects: 114
Study 9324342 — intervention group
Group type: COMPARATOR
Intervention: CVPP chemotherapy (6 cycles)
Number of subjects: 114
Study 9324342 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP chemotherapy (6 cycles) + Radiotherapy (RT)
Number of subjects: 114
Study 9324342 — intervention group
Group type: EXPERIMENTAL
Intervention: AOPE chemotherapy (6 cycles) + Radiotherapy (RT)
Number of subjects: 114
Study 9324342 — intervention group
Group type: EXPERIMENTAL
Intervention: CCOPP/CAPTe chemotherapy (6 cycles)
Number of subjects: 114
Study 8223808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen administered at regular 4h intervals (group 1)
Number of subjects: 104
Study 8223808 — intervention group
Group type: COMPARATOR
Intervention: Sporadic usage of acetaminophen contingent upon a body temperature above 37.9 degrees C (group 2)
Number of subjects: 104
Study 8223808 — intervention group
Group type: COMPARATOR
Intervention: Sporadic usage of acetaminophen (group 2)
Number of subjects: 104
Study 3950253 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg per puff)
Number of subjects: 16
Study 3950253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30075954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol 1.5 mg/day for 6 months
Number of subjects: 26
Study 30075954 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 50 mg/day for 6 months
Number of subjects: 26
Study 27685254 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPULS (impulsivity-focused group intervention)
Number of subjects: 0
Study 27685254 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 24909487 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide 450 mg up to three times daily
Number of subjects: 54
Study 24909487 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study 22105574 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-oriented group program (15 sessions for parents and children)
Number of subjects: 70
Study 22105574 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling (2 appointments for children)
Number of subjects: 70
Study 22105574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment arms
Number of subjects: 70
Study 20839433 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy (Group A)
Number of subjects: 241
Study 20839433 — intervention group
Group type: COMPARATOR
Intervention: Macrodiscectomy (Group B)
Number of subjects: 241
Study 17925053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mola (Amblypharyngodon mola), 600 retinol activity equivalents (RAE), 6 d/week for 9 weeks
Number of subjects: 196
Study 17925053 — intervention group
Group type: COMPARATOR
Intervention: Rui (Labeo rohita) with added retinyl palmitate, 600 RAE, 6 d/week for 9 weeks
Number of subjects: 196
Study 17925053 — intervention group
Group type: COMPARATOR
Intervention: Rui (Labeo rohita), 0 RAE, 6 d/week for 9 weeks
Number of subjects: 196
Study 17220631 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal orlistat with a fat-containing meal
Number of subjects: 0
Study 17220631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral orlistat
Number of subjects: 0
Study 17220631 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal orlistat with a fat-free meal
Number of subjects: 0
Study 12819524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 0
Study 12819524 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 0
Study 11122756 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 4
Study 11122756 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 4
Study 8784758 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.3 g) before running
Number of subjects: 7
Study 8784758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose) before running
Number of subjects: 7
Study 8784758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose) before rest
Number of subjects: 7
Study 8784758 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.3 g) before rest
Number of subjects: 7
Study 7930385 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance subjects (n = 34)
Number of subjects: 430
Study 7930385 — intervention group
Group type: COMPARATOR
Intervention: Nondiagnostic tolerance subjects (NDT, n = 30)
Number of subjects: 430
Study 7930385 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance subjects (IGT, n = 30)
Number of subjects: 430
Study 7930385 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects rendered mildly hyperglycemic by a 24-h glucose infusion (1 mg/kg/min for NDT and 2 mg/kg/min for IGT)
Number of subjects: 430
Study 2905989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 14
Study 2905989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 14
Study 2905989 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 14
Study 30304047 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral (right side) stimulation of the HT7 acupuncture point using a single‐twitch electrical stimulus (1 Hz, 50 mA) throughout the surgery
Number of subjects: 100
Study 30304047 — intervention group
Group type: COMPARATOR
Intervention: Electrodes alone attached to the HT7 point on the right side; no electrical stimulus applied (control group)
Number of subjects: 100
Study 30304047 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral (right side) stimulation of the HT7 acupuncture point
Number of subjects: 100
Study 28856359 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior CSI
Number of subjects: 55
Study 28856359 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior CSI
Number of subjects: 55
Study 26111250 — intervention group
Group type: EXPERIMENTAL
Intervention: Abandonment psychotherapy delivered by certified psychotherapists
Number of subjects: 170
Study 26111250 — intervention group
Group type: EXPERIMENTAL
Intervention: Abandonment psychotherapy delivered by nurses
Number of subjects: 170
Study 26111250 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 170
Study 23710960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 57
Study 23710960 — intervention group
Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 57
Study 21838913 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium micronutrient supplement
Number of subjects: 300
Study 21838913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 19531090 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Multi Protection toothpaste (C)
Number of subjects: 34
Study 19531090 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne Total Protection (S)
Number of subjects: 34
Study 17543818 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine/fentanyl
Number of subjects: 10
Study 17543818 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (patient-controlled analgesia)
Number of subjects: 10
Study 15294856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (screening and treatment for infection)
Number of subjects: 4429
Study 15294856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening revealed to caregivers)
Number of subjects: 4429
Study 15294856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 4429
Study 15294856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4429
Study 11433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic epileptics
Number of subjects: 108
Study 11433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without detectable brain lesions
Number of subjects: 108
Study 11433674 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 9602986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily, at night)
Number of subjects: 24
Study 9602986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g twice daily)
Number of subjects: 24
Study 9602986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 7599759 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 257
Study 7599759 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 257
Study 2403809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and steroids
Number of subjects: 0
Study 2403809 — intervention group
Group type: COMPARATOR
Intervention: Control or comparison group
Number of subjects: 0
Study 359215 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin 100 to 300 mg
Number of subjects: 16
Study 359215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 876
Study 31804894 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 876
Study 31804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (nonbasal phenotype)
Number of subjects: 876
Study 31804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (basal phenotype)
Number of subjects: 876
Study 31804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (overall survival)
Number of subjects: 876
Study 31219721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 2907
Study 31219721 — intervention group
Group type: COMPARATOR
Intervention: Reference Intakes
Number of subjects: 2907
Study 31219721 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 2907
Study 28719285 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel intervention package delivered over 3 months including local rallies, games, rewards, storytelling, drama, competitions, and kitchen makeovers.
Number of subjects: 0
Study 28719285 — intervention group
Group type: COMPARATOR
Intervention: Control group (four villages) with no intervention.
Number of subjects: 0
Study 26581750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose esomeprazole (80 mg + 8 mg/h)
Number of subjects: 215
Study 26581750 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg + 60 mg/h)
Number of subjects: 215
Study 24232362 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program (weekly supervised gym sessions of stationary cycling and resistance exercises, and a twice weekly independent home-based walking program)
Number of subjects: 31
Study 24232362 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Number of subjects: 31
Study 24232362 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 31
Study 20521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parenting
Number of subjects: 55
Study 20521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent negative life events
Number of subjects: 55